Due to novel, promising drugs that are introduced in the treatment of CLL recently, such as non-covalent BTK-inhibitors or bispecific antibodies, the value of idelalisib salvage treatment will remain limited to few patients. Here, BTK is linked to B-cell chronic lymphocytic leukemia.